'It gave me hope': Alzheimer's sufferer, 57, reveals heartbreak after failure of clinical triale
Former New York Times reporter Phillip S Gutis, 57, was diagnosed with Alzheimer's in 2016, placing him in the slim category of the four percent diagnosed before the age of 65. (Source: the Mail online | Health)
Source: the Mail online | Health - March 22, 2019 Category: Consumer Health News Source Type: news

FDA panel: Neuronix Alzheimer ’ s therapy fails to prove efficacy
An FDA advisory panel has recommended against granting de novo clearance to Neuronix’s NeuroAD system intended to slow the progress of mild to moderate Alzheimer’s disease. NeuroAD is approved for use in Europe, Australia and Israel, but the panel found that while it met FDA safety standards, clinical studies did not prove that it is effective. NeuroAD uses focused transcranial magnetic stimulation (TMS) to stimulate target areas of the brain responsible for cognitive functions impaired by Alzheimer’s disease, according to the Yoqneam, Israel-based company. This stimulation is designed to induce long-term...
Source: Mass Device - March 22, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Featured Food & Drug Administration (FDA) Neurological Neuromodulation/Neurostimulation News Well neuronix Source Type: news

D.C. Week: Postpartum Depression Gets Its Own Drug
(MedPage Today) -- Also, a novel Alzheimer's therapy deemed unready for prime time (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - March 22, 2019 Category: Psychiatry Source Type: news

An Alzheimer ’ s Drug Trial Gave Me Hope, and Then It Ended
I was a small piece in the search to find a cure. Now I feel as if I ’ m getting erased, and medical science doesn ’ t have any answers. (Source: NYT Health)
Source: NYT Health - March 22, 2019 Category: Consumer Health News Authors: PHILLIP S. GUTIS Tags: Alzheimer's Disease Drugs (Pharmaceuticals) Memory Dementia Clinical Trials Source Type: news

Biogen halts late-stage Alzheimer ’s trials
Biogen and partner Eisai said they were halting two late-stage clinical trials involving an experimental treatment for Alzheimer ’s disease after determining it would likely fail to help patients. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - March 22, 2019 Category: Pharmaceuticals Source Type: news

Magnetic Device for Alzheimer's Nixed by FDA Advisors
(MedPage Today) -- But " there's probably a signal here, " panelists say (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - March 22, 2019 Category: Neurology Source Type: news

How Will The Failure Of Biogen's Alzheimer's Drug, Aducanumab, Impact R & D?
The death of an important drug like aducanumab will have both a short and a long term effect on Biogen as a company and especially on R&D. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 22, 2019 Category: Pharmaceuticals Authors: John LaMattina, Contributor Source Type: news

Experts question Alzheimer's treatment strategy after Biogen failure
Though some Massachusetts startups and researchers are maintaining a dogged determinedness in targeting a protein called amyloid beta, many are calling Biogen's aducanumab failure the last nail in the coffin. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 22, 2019 Category: American Health Authors: Allison DeAngelis Source Type: news

Ask Well: Why Did I Lose My Sense of Smell?
Impaired smell is common, particularly in the elderly, but in about one in six people, no cause can be identified. (Source: NYT Health)
Source: NYT Health - March 22, 2019 Category: Consumer Health News Authors: RICHARD KLASCO, M.D. Tags: Smell (Olfaction) Sinusitis Allergies Alzheimer's Disease Parkinson's Disease Nerves and Nervous System Air Pollution Source Type: news

Eisai starts phase 3 trials for second Alzheimer's drug after first's failure
Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab. (Source: Reuters: Health)
Source: Reuters: Health - March 22, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Montana State professor wins NSF CAREER award for biosensor diagnostics
(Montana State University) Montana State University's Stephanie McCalla won the $500,000, five-year grant to further her research on switch-like biosensors for diagnosing breast cancer, Alzheimer's disease and more. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 22, 2019 Category: International Medicine & Public Health Source Type: news

Sleep problems, Alzheimer's disease are linked, but which comes first?
(American Physiological Society) A new article explores the pathophysiological factors that link sleep disturbances and Alzheimer's disease. Better understanding of this connection may lead to potential diagnostics and therapeutics for Alzheimer's disease, and other neurodegenerative diseases and dementia. The article is published ahead of print in the Journal of Neurophysiology (JNP). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 22, 2019 Category: International Medicine & Public Health Source Type: news

Hopes Dashed for Aducanumab in Alzheimer's Disease Hopes Dashed for Aducanumab in Alzheimer's Disease
The phase 3 ENGAGE and EMERGE trials, which were assessing the novel amyloid-B-targeting agent aducanumab for Alzheimer's-related dementia, have been discontinued due to futility.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - March 21, 2019 Category: Psychiatry Tags: Neurology & Neurosurgery News Source Type: news

Long-term hormone use after menopause tied to Alzheimer's risk
(Reuters Health) - Women who take hormone replacement therapy (HRT) to ease menopause symptoms like hot flashes and night sweats may be slightly more likely to develop Alzheimer's disease, a large Finnish study suggests. (Source: Reuters: Health)
Source: Reuters: Health - March 21, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Once-Promising Alzheimer's Drug Fails in Phase III
(MedPage Today) -- Futility analysis prompts Biogen and Eisai to stop trials of anti-amyloid agent (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - March 21, 2019 Category: Psychiatry Source Type: news

Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value
Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion of its value on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - March 21, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Another Promising Alzheimer ’ s Drug Trial Ends In Failure: ‘ This One Hurts ’
(CNN) — It’s another devastating blow in the search for a treatment for patients living with Alzheimer’s disease. Pharmaceutical giant Biogen and its Japanese partner Eisai announced Thursday they were halting two phase three clinical trials of a drug that targets the buildup in the brain of beta-amyloid, one of two proteins that researchers believe contribute to the development of Alzheimer’s. The drug, called aducanumab, was the most promising candidate in a field that has been littered with failures. It was so promising that the company was running two phase three trials simultaneously, said neur...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - March 21, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Alzheimer's Disease CNN Source Type: news

Biogen shares plunge as Alzheimer's drug trial disappoints
Biotech halts late-stage trials of experimental treatment, saying it's unlikely to help those with the brain disease (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - March 21, 2019 Category: Consumer Health News Source Type: news

Promising Alzheimer's drug trial ends in failure
A promising drug designed to remove proteins from the brains of Alzheimer's patients has been halted, dealing another blow to the ongoing search for treatment and a cure. (Source: CNN.com - Health)
Source: CNN.com - Health - March 21, 2019 Category: Consumer Health News Source Type: news

Biogen Halts Promising Alzheimer ’s Drug Trials Due to Disappointing Results
Pharmaceutical company Biogen is halting two global phase-three trials testing the once-promising Alzheimer’s drug aducanumab, delivering a late-stage blow to researchers searching for therapies for the incurable degenerative disease. “This disappointing news confirms the complexity of treating Alzheimer’s disease and the need to further advance knowledge in neuroscience,” Biogen CEO Michel Vounatsos said in a statement Thursday. “We are incredibly grateful to all the Alzheimer’s disease patients, their families and the investigators who participated in the trials and contributed greatly...
Source: TIME: Health - March 21, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Drugs onetime Source Type: news

Biogen stock plummets after it abandons Alzheimer ’s drug
At the opening bell, Biogen Inc. lost more than $16 billion in market value after disclosing it would scrap its most advanced Alzheimer's disease drug candidate. Cambridge-based Biogen (Nasdaq: BIIB) and its development partner, Eisai Co. Ltd., are discontinuing two Phase 3 trials of their lead drug, aducanumab, after a so-called "futility analysis" indicated the trials were unlikely to be succeed, according to an early morning press release. Together with Eisai, Biogen had begun two Phase 3 trials… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - March 21, 2019 Category: Health Management Authors: Allison DeAngelis Source Type: news

Anti-epileptics ‘increase risk’ of pneumonia in Alzheimer’s patients
Patients with Alzheimer ’s disease using anti-epileptic drugs have twice the risk of pneumonia compared to non-users, according to researchers. (Source: Nursing Times)
Source: Nursing Times - March 21, 2019 Category: Nursing Source Type: news

Biogen stock plummets after it abandons Alzheimer ’s drug
Biogen Inc. lost more than $17 billion in market value when markets opened Thursday after disclosing a couple hours earlier that it will scrap its most advanced Alzheimer's disease drug candidate. Cambridge-based Biogen (Nasdaq: BIIB) and its development partner, Eisai Co. Ltd., are discontinuing two Phase 3 trials of their lead drug, aducanumab, after a so-called "futility analysis" indicated the trials were unlikely to be succeed, according to an early morning press release. Together with Eisai,… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - March 21, 2019 Category: Health Management Authors: Allison DeAngelis Source Type: news

Researchers discover hidden differences between pathology of CTE and Alzheimer's disease
(Indiana University) An international team of scientists at Indiana University School of Medicine, University of Kansas and the U.K. Medical Research Council have dismantled the belief that Alzheimer's disease and Chronic Traumatic Encephalopathy have made a discovery that offers options for improved diagnosis and potential targeted treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 21, 2019 Category: International Medicine & Public Health Source Type: news

MRC scientists discover unique tau filament structures in head-injury associated dementia
MRC Laboratory of Molecular Biology researchers reveal atomic structures of the abnormal tau filaments associated with chronic traumatic encephalopathy, a head injury-associated neurodegenerative disease, differ in structure from those seen in Alzheimer’s disease. (Source: Medical Research Council General News)
Source: Medical Research Council General News - March 20, 2019 Category: Research Source Type: news

Antiepileptic Drugs Not Tied to Dementia Risk
WEDNESDAY, March 20, 2019 -- Antiepileptic drug (AED) use is not significantly associated with dementia risk in patients in Germany, according to a study published online March 12 in the Journal of Alzheimer's Disease. Louis Jacob, Ph.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 20, 2019 Category: Pharmaceuticals Source Type: news

Will Missed Endpoint Sink Magnetic Tx for Alzheimer's?
(MedPage Today) -- FDA panel to consider inconsistent trial data at Thursday meeting (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - March 20, 2019 Category: Neurology Source Type: news

Study finds key details about 'punch drunk syndrome' and Alzheimer's
Scientists studying damaged brains of boxers and other sports people have found key details about a head injury-linked disease called "punch drunk syndrome" that could help the development of new diagnostics and treatments for Alzheimer's. (Source: Reuters: Health)
Source: Reuters: Health - March 20, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Medical News Today: Study links severe gum disease to raised dementia risk
Another study has linked chronic periodontitis to higher dementia risk. However, it is the first to show that the link is independent of lifestyle factors. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 20, 2019 Category: Consumer Health News Tags: Alzheimer's / Dementia Source Type: news

Alzheimer's Risk Also Linked to 2nd, 3rd, and 4th Degree Family (CME/CE)
(MedPage Today) -- Risk for AD rises even in absence of first-degree family history, but lifestyle changes can reduce risk (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - March 20, 2019 Category: Neurology Source Type: news

FTC & FDA issue warning letters to supplement sellers
Ads abound for products that claim to treat or prevent serious health conditions. Unfortunately, these products often are unproven and useless. Sometimes the ads even make false promises for Alzheimer ’s disease and dementia – conditions for which science has no cure. (Source: NCCAM Featured Content)
Source: NCCAM Featured Content - March 20, 2019 Category: Complementary Medicine Authors: NCCIH Source Type: news

States Seek Financial Relief for Family Caregivers
Lawmakers in California and at least seven other states want to provide state income tax credits for families that need help with home caregiving. (Source: NYT Health)
Source: NYT Health - March 20, 2019 Category: Consumer Health News Authors: SAMANTHA YOUNG, KAISER HEALTH NEWS Tags: Politics and Government State Legislatures Alzheimer's Disease Elderly Law and Legislation Home Health Care Health Insurance and Managed Care Source Type: news

Diabetes and Alzheimer's linked
(Source: MayoClinic.com Full Feed)
Source: MayoClinic.com Full Feed - March 20, 2019 Category: Consumer Health News Source Type: news

Can Brain Wave Stimulation Help Alzheimer & #039;s Patients?
Massachusetts Institute of Technology researchers are using a unique combination of light and sound to improve cognitive and memory impairments similar to those seen in Alzheimer's patients. The noninvasive treatment works by inducing brain waves known as gamma oscillations and so far the team has only performed the treatment on mice.  “When we combine visual and auditory stimulation for a week, we see the engagement of the prefrontal cortex and a very dramatic reduction of amyloid,” said Li-Huei Tsai, director of MIT’s Picower Institute for Lear...
Source: MDDI - March 19, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: R & D Source Type: news

Light, Sound, and Alzheimer ’s; Cocoa for MS Fatigue; Manganese and Parkinson's
(MedPage Today) -- News and commentary from the world of neurology and neuroscience (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - March 19, 2019 Category: Psychiatry Source Type: news

Medical News Today: Light and sound therapy may boost brain function
New evidence suggests that a combined light and sound stimulation therapy could boost brain health and improve the symptoms of Alzheimer's disease. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 19, 2019 Category: Consumer Health News Tags: Alzheimer's / Dementia Source Type: news

AI can predict cognitive development from MRI at birth
By analyzing the white-matter connections of an infant's brain at birth on...Read more on AuntMinnie.comRelated Reading: PET, AI show women's brains age differently than men's Machine learning, fMRI unlock cellular brain properties AI, diffusion MRI can predict outcomes for epilepsy AI helps uncover clues for Alzheimer's disease in MRI data NYMIIS: Next-gen PACS will include 'best-of-breed' AI (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 19, 2019 Category: Radiology Source Type: news

memantine (Namenda)
Title: memantine (Namenda)Category: MedicationsCreated: 11/3/2003 12:00:00 AMLast Editorial Review: 3/19/2019 12:00:00 AM (Source: MedicineNet Alzheimer)
Source: MedicineNet Alzheimer - March 19, 2019 Category: Geriatrics Source Type: news

Berywn biopharm firm taking on Parkinson's, Alzheimer's raises $530K
QR Pharma has now raised more than $4.5M since the start of 2010 through stock and debt sales. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 18, 2019 Category: American Health Authors: John George Source Type: news

Berywn biopharm firm taking on Parkinson's, Alzheimer's raises $530K
QR Pharma has now raised more than $4.5M since the start of 2010 through stock and debt sales. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 18, 2019 Category: Biotechnology Authors: John George Source Type: news

Supplements won't stave off Alzheimer's, doctors warn
As Alzheimer ’s disease and dementia affect a growing number of Americans, efforts to keep brain decline at bay have become big business. But in a piece published in the Journal of the American Medical Association, neurologists at the University of California, San Francisco’s Memory and Aging Center, cautio n consumers that brain health supplements have no proven benefit, calling them “pseudomedicine.” In the strongly worded opinion piece, the researchers stress that there are no known supplements… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 18, 2019 Category: Biotechnology Authors: Caitlin Mullen Source Type: news

Personal Health: When the Benefits of Statins Outweigh the Risks
Knowing the odds of side effects and making sure to get periodic checkups that would pick up an adverse reaction, I chose to focus on the drugs ’ potential benefits. (Source: NYT Health)
Source: NYT Health - March 18, 2019 Category: Consumer Health News Authors: JANE E. BRODY Tags: Cholesterol Statins (Cholesterol-Lowering Drugs) Heart Drugs (Pharmaceuticals) Diet and Nutrition Alzheimer's Disease Source Type: news

Medical News Today: Alzheimer's disease: An eye test could provide early warning
One day, a quick eye test may be able to pick up important information about brain health. Specifically, it may be able to identify signs of dementia. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 18, 2019 Category: Consumer Health News Tags: Alzheimer's / Dementia Source Type: news

Study finds test of protein levels in the eye a potential predictor of (future) Alzheimer's disease
(Boston Medical Center) Low levels of amyloid-β and tau proteins, biomarkers of Alzheimer's disease (AD), in eye fluid were significantly associated with low cognitive scores, according to a new study. These findings indicate that proteins in the eye may be a potential source for an accessible, cost-effective test to predict future Alzheimer's disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 18, 2019 Category: International Medicine & Public Health Source Type: news

Yang Awarded Robert W. Katzman, MD Clinical Research Training Scholarship
Hyun-Sik Yang, MD, of the Department of Neurology, was selected for the 2019 Robert W. Katzman, MD Clinical Research Training Scholarship in Alzheimer ’s and Dementia Research to support his project, “Immunogenetic Alzheimer’s Disease Risk and the Pro (Source: BWH News)
Source: BWH News - March 18, 2019 Category: Hospital Management Source Type: news

Why Is Maria Shriver Passionate About Protecting Your Brain Health?
Every 65 seconds a brain is impacted by Alzheimer's disease, and two-thirds of them belong to women. Maria Shriver explains why women are at the center of this global health crisis — and may also hold the key to unlocking a cure. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 17, 2019 Category: Pharmaceuticals Authors: Claire Coghlan, Contributor Source Type: news

Don't laugh, but I've watched Bohemian Rhapsody 12 times: BONNIE ESTRIDGE on life with Alzheimer's  
I think I’ve now watched Bohemian Rhapsody ten times. I don’t really remember a lot of it, so it’s just as enjoyable every time. Watching the film over and over is a comforting routine. (Source: the Mail online | Health)
Source: the Mail online | Health - March 16, 2019 Category: Consumer Health News Source Type: news

Alzheimer ’s and Longevity Genes: Are They Connected?
(MedPage Today) -- A life-extending gene variant may protect people at risk for AD (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - March 15, 2019 Category: Neurology Source Type: news

A Possible Alzheimer ’ s Treatment With Clicks and Flashes? It Worked on Mice
Researchers hope the techniques can be applied to help people with Alzheimer ’ s. (Source: NYT Health)
Source: NYT Health - March 15, 2019 Category: Consumer Health News Authors: PAM BELLUCK Tags: Alzheimer's Disease Animal Cognition Brain Mice Genetic Engineering Cell (Journal) Massachusetts Institute of Technology your-feed-science Source Type: news

Light and sound stimulus therapy generates a buzz in Alzheimer ’s research world
The often-discouraging search for ways to prevent or treat Alzheimer ’s disease may have flickered to life this week with a bright new idea — and a buzzy new soundtrack as well.In experiments conducted on mice, scientists used light and sound to orchestrate a series of episodes that were marked... (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - March 15, 2019 Category: Science Authors: Melissa Healy Source Type: news